Continence Aids Payment Scheme 2010
I, JUSTINE ELLIOT, Minister for Ageing, formulate this Scheme under section 12 of the National Health Act 1953.
Dated __28 June____ 2010
Justine Elliot
____________________________________
Minister for Ageing
Part 1 Preliminary
1. Name of Scheme
2. Commencement
3. Interpretation
Part 2 Participation in the Scheme
4. Eligibility criteria
5. Application to participate in the Scheme
6. Notification to Medicare Australia CEO
7. Decision that a person has ceased to be eligible
8. When participation ceases to have effect
Part 3 Payments
9. Amount of CAPS payment
10. Payment procedure
11. Payment by instalments
12. Payment to transferred person
13. Payment to approved person
14. Notification of details of payments
Part 4 Representatives and organisations
15. Interpretation
16. Ceasing representation of a person
17. Authorised representative
18. Correspondence recipient
19. Authorised payment recipient
20. Responsible person for a participating person
21. Organisations authorised to receive CAPS payments
Part 5 Miscellaneous
22. Debts
23. Investigations
24. Review of decisions
Schedule
This Scheme is the Continence Aids Payment Scheme 2010.
This Scheme commences on 1 July 2010.
(1) In this Scheme:
Act means the National Health Act 1953.
Amendment Act means the National Health Amendment (Continence Aids Payment Scheme) Act 2010.
approved form, when used in a provision of this Scheme, means a form approved, whether before or after the commencement of this Scheme, by the Secretary or Medicare Australia CEO in writing for the purposes of that provision.
authorised payment recipient, for a participating person, means the person referred to subsection 19(3).
authorised representative means a person referred to in subsection 17(3).
CAPS payment, for a participating person, means:
(a) for a financial year—the amount specified in subsection 9(1); or
(b) for part of a financial year—the amount calculated in accordance with, subsection 9(2).
continence aid means a product intended to assist in the management of incontinence and, for the avoidance of doubt, includes continence-related products.
correspondence recipient means a person referred to in section 18.
eligibility criteria has the meaning given by section 4.
eligible neurological condition means a condition listed in Part 1 of the Schedule.
eligible other condition means a condition listed in Part 2 of the Schedule.
health professional means:
(a) a person engaged in a health care related vocation or profession who must be registered or licensed (however described) under a Commonwealth, State or Territory law in order to practise that vocation or profession; or
(b) a person who is an eligible Aboriginal health worker under the Health Insurance (Allied Health Services) Determination 2009 made under the Health Insurance Act 1973.
Note: Section 10 of the Acts Interpretation Act 1901 deals with references to legislation that has been amended or replaced.
legal representative means a person with legal authority under a law of a State or Territory to act for another person such as a guardian or attorney under a power of attorney.
organisation means an entity, including a body politic, with an Australian Business Number which provides, will provide or will facilitate the provision of continence aids to a participating person, but does not include a person:
(a) with legal authority under a law of a State or Territory to act for the applicant or participating person; or
(b) a person referred to in paragraphs 17(2)(a) to (c) or 19(1)(a) to (c).
participating person means:
(a) a person approved under section 5 to participate in this Scheme; or
(b) a person taken to participate, and to be eligible to participate, in this Scheme under item 3 of the Amendment Act,
unless the person’s participation has ceased to have effect under this Scheme.
Note: Item 3 of the Amendment Act and section 8 of this Scheme deal with when a person’s participation ceases to have effect.
permanent and severe incontinence means frequent and uncontrollable moderate to large loss of urine or faeces which impacts on a person's quality of life and which is unlikely to improve with medical, surgical or clinical treatment regimes.
Secretary includes a person authorised by the Secretary to act on his or her behalf in approving forms for, or related to, this Scheme.
(2) Nothing in this Scheme is intended to affect the operation of any law of a State or Territory that deals with legal representatives.
(3) References to a legal representative in particular provisions and not in others is not intended to limit a legal representative’s powers to act for the represented person.
Part 2 Participation in the Scheme
(1) The eligibility criteria for a person to participate in this Scheme is that the person:
(a) suffers from permanent and severe incontinence:
(i) caused by an eligible neurological condition; or
(ii) caused by an eligible other condition and the person has a Centrelink Pensioner Concession card or entitlement, whether as primary cardholder or a dependant of a cardholder; and
(b) is an Australian citizen or permanent resident within the meaning of those terms in the Australian Citizenship Act 2007; and
(c) is not ineligible because of subsection (2).
Note: Item 3 of the Amendment Act provides that a person who was receiving assistance under the Continence Aids Assistance Scheme immediately before 1 July 2010 is taken to participate in this Scheme from 1 July 2010 subject to complying with that section and, after 30 June 2011, meeting the eligibility criteria in this section.
(2) A person in any of the following categories is not eligible to participate in this Scheme:
(a) (for the avoidance of doubt) people who suffer from transient, rather than permanent and severe, incontinence;
(b) children under 5 years of age;
(c) care recipients, under the Aged Care Act 1997:
(ii) who are receiving an Extended Aged Care at Home (EACH) or Extended Aged Care at Home Dementia (EACHD) package and the care recipient’s care plan includes continence products;
(d) people eligible to receive assistance for continence aids under the Rehabilitation Appliances Program (or replacement program if the name of that program is changed) through the Department of Veterans' Affairs;
(f) a person serving a prison sentence.
(1) A person may apply to the Medicare Australia CEO to participate in this Scheme.
(2) The Medicare Australia CEO must approve a person to participate in this Scheme if:
(a) the applicant meets the eligibility criteria; and
(b) the application is made on the approved form; and
(c) the application:
(i) includes a statement prepared and signed by a health professional certifying that the applicant has been diagnosed by a doctor with an eligible neurological condition or eligible other condition, as the case may be, which has caused permanent and severe incontinence; and
Note: Health professional is defined in subsection 3(1).
(ii) includes any other document or information required by the approved form.
Note: Section 14 of the Amendment Act provides that if an application is refused the Medicare Australia CEO must give the applicant a signed notice that includes the reasons for the decision and advising that the person may apply to the Medicare Australia CEO for a review of the decision. The application for review of the decision is dealt with in section 24 of this Scheme.
(1) A participating person, legal representative or authorised representative must notify the Medicare Australia CEO promptly on becoming aware that the participating person does not meet the eligibility criteria.
Example: A participating person must notify the Medicare Australia CEO if the person begins receiving a high level of residential care in a residential care facility: see subparagraph 4(2)(c)(i).
(2) A legal representative or authorised representative must notify the Medicare Australia CEO promptly on becoming aware that the participating person has died.
Note 1: Item 3 of the Amendment Act provides that, until 1 July 2011, the Medicare Australia CEO cannot make a decision about ineligibility in respect of a person to whom that item applies.
Note 2: Section 15 of the Amendment Act provides that if the Medicare Australia CEO decides that a participating person is not eligible to participate in the scheme, he or she must give the person a signed notice that includes the reasons for the decision and advising that the person may apply to the Medicare Australia CEO for a review of the decision. The application for review of the decision is dealt with in section 24 of this Scheme.
A person’s participation in this Scheme ceases to have effect:
(a) if notification is given under paragraph 6(1)─from the date the person ceased to meet the eligibility criteria; or
(b) if the Medicare Australia CEO decides that the person is not eligible to participate─from the date specified in the determination under section 7.
Note: Where a person entitled to a CAPS payment has died, payment will be made to the estate: see paragraph 10(1)(c).
(1) The amount of the CAPS payment for a financial year is $497.79.
Example: A person applies on 1 August 2010. The person’s CAPS payment is calculated for the period 1 August to 30 June 2011 (inclusive).
(3) A participating person may not receive:
(a) more than the amount of the CAPS payment for a financial year in any one financial year;
(b) more than one payment for the same period in a financial year.
(1) The Medicare Australia CEO must pay a CAPS payment, or an instalment of a CAPS payment, to which a participating person has become entitled under this Scheme to:
(a) the person; or
(b) if there is an authorised payment recipient for the person─the authorised payment recipient; or
(c) if the person has died, the person’s estate.
(2) The CAPS payment must be made:
(a) in one transaction unless the person has elected, in the approved form, to receive the payment in two instalments (except where subsection 11(4) applies); and
(b) by way of electronic funds transfer to the bank account notified, in the approved form, to the Medicare Australia CEO.
(1) A person may elect to receive the CAPS payment in two instalments, worked out in accordance with this section, in a financial year.
(2) If the person is a participating person on 1 July in the financial year:
(a) the first instalment a pro rata amount calculated for the period starting on the day the application was received and ending on 31 December (inclusive) in that financial year, to be paid within 30 days of approval of the application; and
(b) the second instalment is the remaining amount of the CAPS payment, to be paid on or after 1 January but no later than 31 January in the financial year.
(4) If an application under section 5 is received after 31 December in the financial year and is approved, the CAPS payment for that financial year is the amount calculated in accordance with 9(2), to be paid within 30 days of approval of the application.
(1) This section applies to a person who is a participating person because of item 3 of the Amendment Act (transferred person).
(2) The transferred person is entitled to the CAPS payment specified in subsection 9(1):
(a) for the 2010-11 financial year;
(b) and each subsequent financial year as long as the person’s participation has not ceased on a date before 1 July of that financial year.
(3) For the financial year beginning on 1 July 2010, the Medicare Australia CEO must:
(a) make the CAPS payment for the person no later than 30 days after receiving the completed transfer form (transfer form) mentioned in item 3 of the Amendment Act; or
(b) if the person elects to receive the CAPS payment in two instalments, pay half the CAPS payment no later than 30 days after receiving the transfer form and half after 1 January 2011 but no later than 31 January 2011.
(4) For a financial year after 30 June 2011, the CAPS payment for the person must be paid no later than 31 July in that financial year or, if the person has elected to receive the CAPS payment in two instalments, in the manner specified in paragraph 11(2).
(5) If the person gives the transfer form to the Medicare Australia CEO before 1 July 2010, the form is taken to have been provided on 1 July 2010.
(1) This section applies to a person who is a participating person because of an approval under section 5 of this Scheme (approved person).
(2) The approved person is entitled to:
(a) the CAPS payment specified in subsection 9(1)or 9(2), whichever applies in the circumstances, in the financial year in which the application is approved; and
(b) the CAPS payment specified in subsection 9(1) in each subsequent financial year as long as the person’s participation has not ceased on a date before 1 July of that financial year.
(3) The Medicare Australia CEO must make a CAPS payment for the approved person:
(a) if the person is a participating person on 1 July in the financial year:
(i) by 30 July in the financial year; or
(ii) if the payment is by instalments, in the manner specified in subsection 11(2); or
(b) if an application under section 5 is received after 1 July but before 31 December in the financial year and is approved:
(i) within 30 days of approving the application; or
(ii) if the payment is by instalments, in the manner specified in subsection 11(3);or
(c) if an application under section 5 is received after 31 December in the financial year and is approved—within 30 days of approving the application.
(1) The Medicare Australia CEO, as soon as practicable after making a CAPS payment, must give a written statement containing details about the payment to:
(a) the participating person or his or her correspondence recipient; and
(b) if the payment was made to an organisation─the organisation.
Part 4 Representatives and organisations
(1) In this part:
assisted person means:
(a) a person applying to participate in this Scheme; or
(b) a participating person,
who is unable to act on his or her own behalf because of a physical or mental impairment.
In this Part:
(a) if a person is recognised as representing another person because of a particular status under the social security law or veterans’ entitlements law, and the person ceases to hold that status, the person’s representation of the other person under this Scheme is also taken to cease;
(b) if a person may authorise, in accordance with this Part, another to do something, the person may also revoke the authorisation by notice in writing to the Medicare Australia CEO;
(c) if a person is authorised, in accordance with this Part, to do something and wishes to end the arrangement, the person may cease the arrangement by notice in writing to the Medicare Australia CEO.
(1) This section applies to an assisted person who does not have a legal representative.
(4) An authorised representative must act in the interests of the assisted person at all times.
An applicant, participating person or an assisted person’s legal representative or authorised representative may authorise, in the approved form, another person (correspondence recipient) to receive correspondence under this Scheme for the applicant or participating person.
(1) One of the following people may receive payments as agent for a participating person if the conditions mentioned in subsection (2) are satisfied:
(b) the person recognised as the participating person's trustee or agent for the purposes of veterans' entitlements; or
(c) a responsible person approved as an authorised payment recipient under section 20; or
(d) an organisation authorised in accordance with subsection 21(2).
(a) the person who is to receive the payments as agent for the participating person has been notified to the Medicare Australia CEO, in the approved form, that that person is to receive the payments; and
(b) if the applicant or participating person has a legal representative—the Medicare Australia CEO has not been notified by the legal representative that the CAPS payments are to be made to another person in accordance with this Scheme.
(1) The Secretary may approve an individual to represent an assisted person or a minor:
(a) as an authorised representative to act for the person; or
(b) as an authorised payment recipient to receive payments as agent of the person; or
(a) as both (a) and (b).
(2) However, the Secretary must not approve an individual unless the Secretary is satisfied that:
(b) if the assisted person has a legal representative, or representation by a person referred to in paragraph 17(2)(a) or (b) or 19(1)(a) or (b)—the representative does not oppose the approval; and
(a) the individual provides care or assistance to the person; and
(b) the arrangement for the receipt of CAPS payments is for the benefit of the person; and
(c) the individual seeking approval will use the funds only for the purpose for which they are provided.
(1) In paragraphs (4)(c), (d), (e) and (f) and subsections (5) and (6), a reference to a “participating person” includes a former participating person and, where the context permits, an authorised representative or correspondence nominee.
(3) If the organisation agrees to receive the CAPS payments as agent, the organisation must provide details to the Medicare CEO for the payments in the approved form.
(4) The organisation must comply with the following obligations:
(a) assist the participating person to obtain continence aids that are appropriate to his or her needs; and
(b) assist the participating person to use the CAPS payment as a contribution towards to the cost of purchasing continence aids; and
(i) the person has ceased to meet the eligibility criteria; or
(ii) the person wishes to terminate the payment arrangement with the organisation; and
(g) inform the Medicare Australia CEO promptly on becoming aware that the participating person does not meet the eligibility criteria.
(a) is not operating to the benefit of the participating person; or
(b) the organisation has not complied with an obligation imposed by this Scheme in respect of any participating person.
(8) If a direction is given under subsection (7):
(a) the Medicare Australia CEO must comply with the direction; and
(b) the Secretary must inform the participating person and the organisation in writing that the organisation is no longer able to act as an authorised payment recipient.
If a participating person or former participating person has received, either directly or through an agent, a CAPS payment to which the person was not entitled, the amount paid is a debt due to the Commonwealth, recoverable by the Medicare Australia CEO.
The Medicare Australia CEO may conduct investigations, as he or she thinks appropriate, in order to ensure that an applicant or a participating person meets the eligibility criteria.
(1) For sections 14 and 15 of the Act, a person aggrieved by a decision under section 5 or 7 of this Scheme may apply, in the way set out in subsection (2), to the Medicare Australia CEO for review of the decision.
(2) The application for review must:
(a) be made by written notice given to the Medicare Australia CEO within 28 days, or such longer period as the Medicare Australia CEO allows, after the day on which the person received notice of the decision; and
(b) set out the reasons for making the request.
Note: Sections 14 and 15 of the Act provide for the reconsideration of decisions by the Medicare Australia CEO and review of such decisions by the Administrative Appeals Tribunal.
Part 1 - Eligible neurological condition
Category 1 | SPINA BIFIDA and SYRINGOMYELIA |
| Arnold-Chiari Syndrome |
| Arthrogryposis |
| Caudal Regression Syndrome |
| Developmental Cord Disorder |
| Holoprosencephaly |
| Malformation of Spinal Cord |
| Sacral Agenesis |
| Spinal Agenesis |
| Spinal Cord Congenital Abnormality |
| Spinal Dysraphism |
| Spinal Hemangioma |
| Vater Syndrome/Vacterl Syndrome |
|
|
Category 2 | CEREBRAL PALSY |
| Dystonic Cerebral Palsy |
| Hereditary Spastic Paralysis |
| Spastic Quadriplegia |
|
|
Category 3 | INTELLECTUAL DISABILITY |
| 2-Hydroxyglutaric Aciduria |
| Agenesis of Corpus Callosum |
| Angelman Syndrome |
| Apert Syndrome |
| ATRX Syndrome |
| Bardot Biedl Syndrome |
| Batten Disease |
| Beare-Stevenson Syndrome |
| Cats Cry Syndrome/Cri Du Chat Syndrome |
| Cerebral Migration Disorders |
| Charge Syndrome |
| Chime Syndrome |
| Chromosomal Abnormalities/Disorders |
| Chromosome 1 Deletion |
| Chromosome 13q Deletion Syndrome |
| Chromosome 15q Duplication Syndrome |
| Chromosome 18q Deletion Syndrome |
| Chromosome 1p36 Deletion Syndrome/Mono 1p36 |
| Chromosome 22 Ring |
| Chromosome 2q Deletion Syndrome |
| Chromosome 9p Deletion Syndrome |
| Chromosome 9q Deletion Syndrome |
| Chromosome Xp Duplication |
| Cockayne Syndrome |
| Coffin-Lowry Syndrome |
| Cognitive Impairment |
| Cohen Syndrome |
| Congenital Hydrocephalus |
| Congenital Neurological Infections |
| Cornelia de Lange Syndrome |
| Costello Syndrome |
| Cowden Disease |
| Developmental Delay |
| Developmental Delay associated with Autism, Autism Spectrum Disorder and Aspergers Syndrome |
| Down Syndrome/Trisomy 21 |
| Dravet Syndrome |
| Edwards Syndrome/Trisomy 18 |
| Fragile X Syndrome |
| Fumarase Deficiency |
| GLUT1-DS Condition |
| Glutaric Aciduria Type 1 |
| Goldenhar’s Syndrome |
| Hunter Syndrome |
| Hurler-Scheie Syndrome |
| Hypomyelination |
| Incomplete Corpus Callosum/Aicardi Syndrome |
| Inversion Duplication of Chromosome 8 |
| Jacobsen Syndrome/11q Chromosome Deletion |
| Joubert Syndrome |
| Kabuki Syndrome |
| Langer-Gideon Syndrome |
| Lawrence Moon Biedel Syndrome |
| Lennox-Gastaut Syndrome |
| Lesch-Nyhan Syndrome |
| Lissencephaly |
| Lowe Syndrome |
| Mannosidosis |
| Maple Syrup Urine Disease |
| Meningitis |
| Menkes Syndrome |
| Microcephaly |
| Mitochondrial Deficiency |
| Mowat-Wilson Syndrome |
| Mucolipidosis IV |
| Myotonic Dystrophy (Type 1) |
| Neonatal Hypoxia |
| Neonatal Onset Multi-system Inflammatory Disease |
| Normal Pressure Hydrocephalus |
| OHDO Syndrome |
| Opitz Trigonocephaly Syndrome |
| Ohtahara Syndrome |
| Ouvrier Syndrome |
| Pallister-Killian Mosaic Syndrome |
| Periventricular Leukomalacia |
| Peroxisome Biogenesis Disorder |
| Phelan McDermid Syndrome/22q 13 Deletion Syndrome |
| Phenylketonuria |
| Polymicrogyria |
| Pontocerebellar Hypoplasia |
| Prader-Willi Syndrome |
| Pyruvate Dehydrogenase Deficiency/Leigh's Disease |
| Rare Congenital Neurological Syndromes and Conditions |
| Rasmussen's Disease |
| Rett Syndrome |
| Rubinstein-Taybi Syndrome |
| Schizencephaly |
| Sensory Integration Disorder/Dysfunction |
| Smith-Lemli-Opitz Syndrome |
| Smith-Magenis Syndrome |
| Sotos Syndrome |
| Sturge-Weber Syndrome |
| Subcortical Band Heterotopia |
| Translocation of Chromosome 2 |
| Translocation Trisomy 5/18 |
| Trichothiodystrophy |
| Trisomy 10 |
| Trisomy 13 |
| Trisomy 20p |
| Trisomy 47 |
| Trisomy 4p |
| Trisomy 9 |
| Tuberous Sclerosis |
| Turner Syndrome |
| Urea Cycle Defect |
| Valproate Embryopathy |
| Velocardiofacial Syndrome |
| West Syndrome |
| Williams Syndrome |
| Wolf-Hirschhorn Syndrome |
| X-Linked Adrenoleukodystrophy |
| Young-Simpson Syndrome |
|
|
Category 4 | PARAPLEGIA and QUADRIPLEGIA |
| Paraparesis |
| Spinal Cord Compression |
| Spinal Cord Infarction |
| Spinal Damage |
| Syringomyelia |
| Tetraplegia |
| Transverse Myelitis |
|
|
Category 5 | ACQUIRED NEUROLOGICAL CONDITIONS |
| Acquired Brain Injury |
| Adhesive Arachnoiditis |
| Alcoholic Encephalopathy |
| Alzheimer's Disease |
| Arachnoiditis |
| Ascending Polyneuropathy |
| Astrocytoma |
| Autonomic Neuropathy Disease |
| Basal Ganglia Infarction |
| Benign Meningioma |
| Brown-Sequard Syndrome |
| Cauda Equina Lesion |
| Cerebral Abscess (Cryptococcus) |
| Cerebral Aneurysm |
| Cerebral Anoxia |
| Cerebral Toxoplasmosis |
| Cerebral Tumour |
| Cerebrovascular Disease |
| Chronic Hypoxia |
| Chronic Inflammatory Demyelination Polyneuropathy (CIDP) |
| Cortical-Basal Ganglionic Degeneration |
| Dementia |
| Developmental/Motor Dyspraxia |
| Diabetic Autonomic Neuropathy |
| Diabetic Neuropathic Bladder |
| Dorsal Pontine Band Syndrome |
| Encephalitis |
| Ependymoma |
| Epilepsy |
| Focal Cerebral Degeneration |
| Glioblastoma Multiforme |
| Glioblastoma of Spine |
| Hepatic Encephalopathy |
| Hydrocephalus |
| Hypoxic Brain Damage |
| Inoperable Neurogenic Incontinence |
| Intracerebral Haemorrhage |
| Korsakoff’s Syndrome |
| Leuco Posterior Encephalopathy |
| Lewi Body Disease |
| Macroencephaly |
| Malignant Meningioma |
| Metastatic Carcinoma with Neurological Syndrome |
| Multiple Systems Atrophy |
| Myopathy |
| Nemaline Myopathy |
| Oligodendroglioma |
| Pachymeningitis |
| Picks Disease |
| Pilocytic Astrocytoma |
| Poliomyelitis |
| Polymyoneuropathy |
| Primary Dystonia (case by case) |
| Progressive Systemic Sclerosis |
| Sacral Neuroplexy |
| Sacral Plexopathy |
| Schizophrenia (Catatonic) |
| Spinal Canal Disease |
| Spinal Chordoma |
| Spinal Ependymoma |
| Spinal Sacral Chordoma |
| Spinal Tumour |
| Stroke/Cerebrovascular Accident (CVA) |
| Subarachnoid Haemorrhage |
| Subdural Haematoma |
| Vascular Dementia |
|
|
Category 6 | DEGENERATIVE NEUROLOGICAL DISEASES |
| Alexander Disease |
| Amyotrophic Lateral Sclerosis |
| Ataxia Telangiectasia |
| Cauda Equina Syndrome |
| Cervical Canal Stenosis |
| Cervical Myelopathy |
| Creutzfeldt-Jakob Disease (CJD) |
| Cytochrome C Oxidase Deficiency |
| Dejerine-Sottas Disease |
| Demyelinating Neuropathy |
| Demyelination of White Matter |
| Fahr's Disease |
| Friedreich’s Ataxia |
| Guillain Barre Syndrome |
| Huntington Chorea/Disease |
| Hypoxic Ischaemic Encephalopathy |
| Idiopathic Axonal Neuropathy |
| Kugelberg-Welander Syndrome |
| Machado Joseph Disease |
| Metachromatic Leukodystrophy |
| Mitochondrial Myopathy with Encephalopathy |
| Morquio Syndrome |
| Motor Neurone Disease |
| Multiple Sclerosis |
| Muscular Dystrophy |
| Myoneural Disorders |
| Neuroaxonal Dystrophy |
| Neurofibromatosis NF |
| Neurogenic Bowel |
| Niemann-Pick Disease Type C |
| Pallister-Hall Syndrome |
| Parkinson Disease |
| Parkinsonism |
| PEHO Syndrome (Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy) |
| Pelizaeus Merzbacher Disease |
| Primary Lateral Sclerosis |
| Progressive Supranuclear Palsy/Steele Richardson Syndrome |
| Sanfilippo Syndrome |
| Sarcoidosis of the Brain |
| Shy-Drager Syndrome |
| Spinal Cord Syndrome |
| Spinal Degeneration |
| Spinal Muscular Atrophy Type 1 |
| Spinal Muscular Atrophy Type 2 |
| Spinocerebellar Degeneration |
| Stiff-Mans Syndrome |
| Striato-Nigral Degeneration |
| Vascular Myelopathy |
| Wallerian Degeneration of White Matter |
| Wilson's Disease |
|
|
Category 7 | BLADDER (BOWEL) INNERVATION DISORDERS |
| Atonic Bladder/Hypotonic Bladder |
| Bladder Exstrophy |
| Bladder Innervation Urgency |
| Cloacal Exstrophy |
| Cystocele (not suitable for surgery) |
| Dystonic Bladder |
| Ectopia Vesica |
| Hirschsprung's Disease |
| Linear Sebaceous Nevus Genetic |
| Myasthenia Gravis |
| Neurogenic Bladder |
| Neuronal Intestinal Dysplasia |
| Neuropathic Bladder |
| Post Bladder Surgery |
| Prostatectomy with nerve removal |
| Prune Belly Syndrome |
| Pudendal Nerve Palsy |
| Radical Prostatectomy |
| Schmidli Autonomic Neuropathy |
| Smooth Muscle Myopathy |
| Sphincter Deficiency |
| Spinal Stenosis |
Part 2 - Eligible other condition
Code 8 | OTHER |
| Anal Carcinoma |
| Anal Fistula |
| Anorectal Malformation |
| Anterior Prolapse |
| Bilateral Nephrostomy Tubes |
| Bladder Cancer |
| Bladder Instability |
| Bladder Muscle Dysfunction |
| Bladder Neck Dysfunction |
| Bladder Neck Fibrosis |
| Bladder Prolapse |
| Bowel Cancer |
| Bowel Prolapse |
| Cervical Cancer |
| Chronic Urinary Retention |
| Congenital Epispadias |
| Detrusor Instability |
| Detrusor Overactivity |
| Enterocutaneous Fistula |
| Hypertonic Bladder |
| Imperforate Anus |
| Irradiated Rectum/Radiation Proctitis |
| Posterior Urethral Valve Syndrome |
| Prostate Cancer |
| Prostate Disease |
| Rectal Prolapse |
| Rectal Ulcer Syndrome |
| Severe Ulcerative Proctitis/Ulcerative Colitis |
| Spastic Bladder |
| TURP |
| Urethral Stenosis |
| Urinary Fistula |
| Uterine Cancer |
| Uterine Prolapse |
| Vaginal Prolapse |
| Vesico-Vaginal Fistula |
| Vulva Cancer |